Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction.
Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction.
复制标题
DOI：
10.1097/fjc.0000000000000223
复制
发表时间：
2015-06
影响因子：
3
通讯作者：
Falsoleiman H
中科院分区：
文献类型：
--
作者：
Gholamzadeh A;Amini S;Mohammadpour AH;Vahabzadeh M;Fazelifar AF;Fazlinezhad A;Dehghani M;Moohebati M;Dastani M;Malaekeh-Nikouie B;Falsoleiman H
心律失常是心肌梗死（MI）后猝死的首要原因。最近动物模型显示，促红细胞生成素（EPO）可降低MI后心律失常的发生率。我们研究了40例ST段抬高型心肌梗死患者给予33，000 IU EPO对心肌梗死后心律失常发生的影响，这些患者被随机分配到EPO组或安慰剂组。心脏病专家在经皮冠状动脉介入治疗（PCI）后24小时内使用完整的12导联配置盲法记录心律失常。随后，在MI后2周内检查CK-MB、血液学和血流动力学数据。两组心律失常发生率比较有显著性差异（EPO组20%，安慰剂组35%，P = 0.043）。然而，两组之间心律失常类型没有观察到显着差异。24 h内两组CK-MB水平差异无统计学意义（P = 0.186）。PCI术后2周血液学和血流动力学指标无明显变化。ST段抬高型心肌梗死患者接受直接PCI和标准抗血小板治疗后，给予大剂量EPO可降低心律失常的发生率。对于结果的临床解释，需要进一步精心设计的试验。
Arrhythmia is the foremost cause of sudden death after myocardial infarction (MI). Animal models have recently shown that erythropoietin (EPO) can reduce the incidence of arrhythmia after MI. We investigated the effects of administrating 33,000 IU EPO on the occurrence of post-MI arrhythmia in 40 patients with ST-elevation MI who were randomly assigned in either EPO or placebo groups. Arrhythmias were blindly documented using full 12-lead configuration during 24 hours after percutaneous coronary intervention (PCI) by a cardiologist. Afterward, CK-MB, hematologic, and hemodynamic data were examined within 2 weeks after MI. A comparison made between the 2 groups showed significant differences in the incidence of arrhythmias (20% in EPO group and 35% in placebo group, P = 0.043). However, no significant differences in type of arrhythmias were observed between the groups. There was no significant difference between levels of CK-MB in the 2 groups during 24 hours (P = 0.186). Hematologic and hemodynamic data showed no significant changes 2 weeks after PCI. High-dose administration of EPO in patients with ST-elevation MI who have been treated by primary PCI and standard antiplatelet therapy reduces the occurrence of arrhythmias. For clinical interpretation of the results, further well-designed trials are required.